Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sana Biotechnology (SANA)
NASDAQ:SANA
Holding SANA?
Track your performance easily
SANA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.29 - $12.00
Previous Close$2.78
Volume1.60M
Average Volume (3M)1.46M
Market Cap
$620.69M
Enterprise Value$517.76M
Total Cash (Recent Filing)$199.01M
Total Debt (Recent Filing)$96.08M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Mar 13, 2025EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding223,268,889
10 Day Avg. Volume2,025,622
30 Day Avg. Volume1,462,095
Standard Deviation0.26
R-Squared0.07
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.93
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$11.67Price Target Upside319.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Sana Biotechnology News
PremiumCompany Announcements
Sana Biotechnology, Inc. Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's cash runway is extended into 2026 due to strategic changes and anticipated reduction in operating cash burn, providing more financial stability for ongoing projects.
Innovative Therapeutic PlatformsSana's non-viral genetic engineering platform allows for the development of allogeneic CAR-T cells that can evade the immune system, promoting therapeutic viability.
Strategic DevelopmentSana Biotechnology is prioritizing its development efforts on Type 1 diabetes, B-cell autoimmune diseases, and B-cell malignancies, indicating a strategic shift to a potentially untapped market opportunity.
Bears Say
Competitive PressureThe company is de-prioritizing its SC291 program for treatment of B-cell malignancies due to increased competition in blood cancers.
Financial PerformanceR&D and SG&A expenses were higher than estimated, which may impact the company's financial health.
Program DelaysThe company has pushed back the initial proof of concept data release for its pancreatic islet cell program, indicating potential delays.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $2.29 and its highest was $12.00 in the past 12 months.
What is Sana Biotechnology’s market cap?
Currently, no data Available
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Mar 13, 2025 which is in 81 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Nov 08, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.257 by $0.007.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -$0.24.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 223,268,890 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.257. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Among the largest hedge funds holding Sana Biotechnology’s share is Flagship Pioneering Inc.. It holds Sana Biotechnology’s shares valued at 104M.
---
Sana Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.67 (319.78% Upside)
$11.67 (319.78% Upside)
Blogger Sentiment
Neutral
SANA Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 25.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.65%
12-Months-Change
Fundamentals
Return on Equity
-92.90%
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases.
---
SANA Stock 12 Month Forecast
Average Price Target
$11.67
▲(319.78% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
BioMarin Pharmaceutical
―
Best Analysts Covering SANA
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-29.38%
reiterated a buy rating 2 months ago
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -29.38% per trade.
---